This article discusses a new approach in the treatment of multi-drug resistant HIV (MDR-HIV). Get ready for some links. It's a biologic medication, called Ibalizumab. A biologic is a pharmaceutical produced by synthesizing living materials for a medical application. This particular medication has been in development since the early 2000's. This antibody was humanized via a mouse. It binds the CD4, which is affected by HIV.
It's estimated, out of the million + people being treated for HIV in the USA, over 10,000 have MDR-HIV. This approach may only help a small population at this time, but it's a step. This drug is administered every 2 weeks intravenously.
This shows how busy the researchers have been over the last several decades. Unfortunately, it isn't a quick process. Even now, it could be years, before this medication is widely available. That's if everything goes well. Even if it fails, the research will be invaluable.
Cya...
No comments:
Post a Comment